Sprint Bioscience
Sprint Bioscience is an agile and innovative company that develops pharmaceuticals in the areas of cancer. Since our inception in 2009 we have built a body of solid expertise and achieved a world leading position, thanks to our dedicated and skilled employees and our effective methodology. OUR BUSINESS CONCEPT
Our strategy is to work with a broad portfolio of projects which we quickly develop in
15/06/2026
The Sprint Bioscience team with CBO Anne-Marie Wenthzel-Buckhöj and CSO Martin Andersson, is gearing up for in San Diego next week.
As the world’s largest biotech gathering, BIO International Convention by Biotechnology Innovation Organization unites our industry to shape the future of healthcare. It’s where innovation meets opportunity, and we’re looking forward to connecting. Our meeting schedule is nearly full, but there’s still an opportunity to connect, reach out via the partnering system to secure a conversation ➡️🔐 https://partner.bio.org/
Sweden will be strongly represented, with a dynamic delegation spanning biotech, pharma, medtech, and life science services. At the Swedish Pavilion, you’ll experience the breadth of Sweden’s life science ecosystem (and cinnamonbuns), from established global companies to pioneering startups, demonstrating how Swedish innovation is driving the next wave of healthcare solutions through new technologies and partnerships. Let’s explore new possibilities in oncology and drug development together.
📍 Visit the Swedish Pavilion ( #3417), next to the registration area and the Digital Health & AI Zone.
10/06/2026
Sprint Bioscience CEO Johan Emilsson presented the company at Aktiedagarna Stockholm, an investor event hosted by Aktiespararna on June 9. During the session, he provided an overview of our operations, strategy, and pipeline, followed by a Q&A discussion.
The full presentation and subsequent Q&A session is available here🎥 https://sprintbioscience.com/sv/film/aktiedagarna-stockholm-2026/
04/06/2026
Sprint Bioscience has commissioned Aktiespararna (the Swedish Shareholders’ Association) and its research service, Analysguiden, to publish an initiation report focused on our operations, business model, and pipeline.
The report is now available: https://www.aktiespararna.se/analyser/sprint-bioscience-innovation-och-affar
In addition to this CEO Johan Emilsson will present the company at Aktiedagarna in Stockholm on June 9 at 16:00 CEST. More information about the event can be found here: 🔗https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-68173
The event will be live-streamed and no registration is required:
🎥https://invitepeople.com/public/events/fa647c6285/pages/ea19175b1c
Please note that the main language of the event is Swedish.
Sprint Bioscience: Innovation och affär | Aktiespararna Sprint Bioscience intar en speciell roll inom svensk läkemedelsutveckling. Bolaget har en relativt omfattande preklinisk portfölj av olika program inom innovativ cancerforskning och vi räknar med att dessa program ska tillåta bolaget att fortsätta göra licensaffärer. Förra årets affär med ...
Klicka här för att få din sponsrade notering.
Typ
Telefon
Webbplats
Adress
Hälsovägen 7
Huddinge
14152